Hi,Until now, Layton has kept his promises he made after the merger.But itit seems like the market expects a raise af new capital, which means a massive dilution with millions of new shares.My hope is still that reducing the costs with generation a cash flow (Dermacan) can avoid this.But if AusCann need cash, what a about bonds or something else to bridge the time until CPAT1 is ready, which could be our cash cow.For me it seems like a better solution to raise cash than a massive dilution which is deadly for current shareholders, who are already sitting on a 50 percent loss or much more.
- Forums
- ASX - By Stock
- AC8
- Ann: AusCann Receives Positive MOC from the U.S. FDA for CPAT-01
Ann: AusCann Receives Positive MOC from the U.S. FDA for CPAT-01, page-35
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)